Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 7, 2010

Primary Completion Date

April 2, 2011

Study Completion Date

April 2, 2011

Conditions

Hyperparathyroidism, Secondary

Interventions

DRUG

Placebo

Single IV injection.

DRUG

Etelcalcetide

Single IV injection. The initial dose was 5 mg and dose escalation proceeded with subsequent doses of 10 mg, 20 mg, 40 mg and 60 mg.

Trial Locations (5)

Cypress

Shreveport

Houston

Brisbane

Melbourne